Cart
sales@molnova.com
Remetinostat
CAS No. 946150-57-8
Remetinostat( SHP-141 )
Catalog No. M24995 CAS No. 946150-57-8
Remetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 32 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 46 | In Stock |
|
| 25MG | 91 | In Stock |
|
| 50MG | 145 | In Stock |
|
| 100MG | 233 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRemetinostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionRemetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes.
-
DescriptionRemetinostat is a hydroxamic acid-based inhibitor of histone deacetylase enzymes. It is under development for the treatment of cutaneous T-cell lymphoma.
-
In Vitro——
-
In Vivo——
-
SynonymsSHP-141
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number946150-57-8
-
Formula Weight323.34
-
Molecular FormulaC16H21NO6
-
Purity>98% (HPLC)
-
SolubilityDMSO:150 mg/mL (463.91 mM; Need ultrasonic)
-
SMILESCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCCC(=O)NO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.
molnova catalog
related products
-
KA2507
KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.
-
SR-18292
SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
-
CI-994
A potent, selective class I HDAC inhibitor with IC50 of 0.9/0.9/1.2 uM for HDAC1/2/3, respectively.
